Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. - Devillier R; Raffoux E; Rey J; Lengline E; Ronchetti AM; Sebert M; Boissel N; Robin M; Vey N; Kiladjian JJ; Dombret H; Cluzeau T (British journal of haematology, 2016)